CRDL Stock Summary and Trading Ideas (Cardiol Therapeutics - Class A Common Shares | NASDAQ:CRDL)

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Cardiol Therapeutics - Class A Common Shares trades on the NASDAQ stock market under the symbol CRDL.

As of December 12, 2025, CRDL stock price declined to $1.08 with 314,148 million shares trading.

CRDL has a beta of 1.71, meaning it tends to be more sensitive to market movements. CRDL has a correlation of 0.14 to the broad based SPY ETF.

CRDL has a market cap of $108.00 million. This is considered a Micro Cap stock.

In the last 3 years, CRDL traded as high as $3.12 and as low as $.45.

CRDL has underperformed the market in the last year with a return of -20.6%, while the SPY ETF gained +14.0%. In the last 3 month period, CRDL fell short of the market, returning +0.9%, while SPY returned +4.0%. However, in the most recent 2 weeks CRDL has outperformed the stock market by returning +2.9%, while SPY returned -0.2%.

CRDL support price is $1.03 and resistance is $1.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRDL shares will trade within this expected range on the day.